DocGo (NASDAQ:DCGO) Earns Buy Rating from Needham & Company LLC

DocGo (NASDAQ:DCGO)‘s stock had its “buy” rating restated by research analysts at Needham & Company LLC in a research report issued on Tuesday,Benzinga reports. They currently have a $3.00 target price on the stock. Needham & Company LLC’s price objective suggests a potential upside of 361.54% from the stock’s previous close.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of DocGo in a report on Monday, December 29th. One analyst has rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, DocGo presently has an average rating of “Hold” and a consensus target price of $2.25.

DocGo Stock Down 1.1%

Shares of NASDAQ DCGO opened at $0.65 on Tuesday. The stock has a market capitalization of $63.58 million, a PE ratio of -1.25 and a beta of 0.95. The firm has a fifty day moving average of $0.77 and a 200-day moving average of $1.03. DocGo has a 52-week low of $0.60 and a 52-week high of $2.89.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Neuberger Berman Group LLC purchased a new stake in DocGo during the fourth quarter worth approximately $29,000. Cerity Partners LLC acquired a new stake in DocGo in the 2nd quarter valued at $37,000. Public Employees Retirement System of Ohio purchased a new stake in shares of DocGo in the fourth quarter worth about $40,000. Engineers Gate Manager LP acquired a new stake in shares of DocGo in the second quarter valued at about $52,000. Finally, Royce & Associates LP acquired a new stake in shares of DocGo in the third quarter valued at about $64,000. 56.44% of the stock is owned by institutional investors and hedge funds.

DocGo News Summary

Here are the key news stories impacting DocGo this week:

• Positive Sentiment: Management set 2026 revenue guidance of $290M–$310M and reiterated a push toward profitability while saying it is exploring strategic alternatives — a forward-looking plan that can support valuation if execution and margin improvement follow. DocGo outlines 2026 revenue guidance of $290M–$310M as company targets profitability and explores strategic alternatives
• Positive Sentiment: Q4 revenue beat consensus and management raised near-term outlook, which triggered an initial strong intraday rally (reports noted a ~15% jump after results). This revenue upside supports the company’s growth story despite other headwinds. DocGo shares surge 15% on Q4 revenue beat and raised guidance
• Neutral Sentiment: Full Q4 earnings call transcript is available — management provided color on the revenue beat, profitability timeline, and the rationale behind strategic-alternatives exploration; investors should read the transcript for details on cadence and capital allocation. DocGo Inc. (DCGO) Q4 2025 Earnings Call Transcript
• Negative Sentiment: Despite the revenue beat, EPS missed badly — the company reported a sizable per-share loss that was well below estimates, which is keeping investor focus on profitability execution and potential dilution. DocGo Inc. (DCGO) Reports Q4 Loss, Beats Revenue Estimates
• Negative Sentiment: Reported revenue was down year-over-year due to the wind-down of the MIG business, and profitability metrics remain negative (net margin and ROE). Those structural headwinds help explain why some of the initial rally faded as investors dig into the quality of revenue and near-term cash flow. DocGo Announces Fourth Quarter and Full Year 2025 Results

DocGo Company Profile

DocGo, Inc is a U.S.-based integrated healthcare company that delivers on-demand and mobile healthcare services. The company’s business model centers on deploying customized medical clinics paired with a digital care platform to bring primary and acute care directly to patients. Through a combination of telemedicine and over-the-road medical units, DocGo addresses routine medical exams, chronic disease management, occupational health screenings, specialist consultations and urgent care interventions.

In addition to its mobile clinic fleet, DocGo’s digital platform offers 24/7 virtual care, facilitating remote consultations via video, phone or secure messaging.